PMV Pharmaceuticals, Inc. (PMVP) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. PMV Pharmaceuticals is a clinical-stage precision oncology company developing small molecule, tumor-agnostic therapies targeting p53 mutations. The company has no approved products and has incurred losses since its inception in 2013. Its lead product candidate, rezatapopt, is in a Phase 1/2 clinical trial (PYNNACLE) and received Orphan Drug Designation in March 2026 for specific ovarian cancers.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(18.0) million | $(17.4) million |
| Operating Expenses | $19.0 million | $21.6 million |
| Cash & Cash Equivalents | $39.1 million | $38.0 million |
| Marketable Securities | $54.4 million | $75.0 million |
| Total Liquidity | $93.5 million | $113.0 million |
| Accumulated Deficit | $(464.5) million | $(386.1) million |
| Net Cash Used in Operating Activities | $(19.7) million | $(18.3) million |
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses decreased by $2.5 million (12%) compared to Q1 2025. This was driven by a $2.1 million decrease in Research and Development (R&D) costs, primarily due to lower contractual costs for clinical research organizations (CROs), partially offset by a $0.4 million increase in personnel-related costs.
- General and Administrative (G&A): G&A expenses decreased by $0.4 million, attributed to reductions in personnel expenses and finance/legal support costs.
- Interest Income: Net interest income declined by $0.9 million to $0.98 million, resulting from lower interest rates and reduced balances in interest-bearing securities.
- Income Tax Benefit: The company recorded no income tax benefit in Q1 2026, compared to a $2.2 million benefit in Q1 2025 derived from the sale of New Jersey tax credits and NOLs. The company reached the program sales limit in the prior year.
- Liquidity: Total financial assets (cash, equivalents, and marketable securities) decreased by approximately $19.4 million quarter-over-quarter due to operating cash burn and net investment activity.
Guidance, Outlook, and Risks
- Development Timeline: Management plans to submit a New Drug Application (NDA) for rezatapopt to the FDA in the first quarter of 2027 for the treatment of platinum-resistant/refractory ovarian cancer with TP53 Y220C mutations.
- Liquidity Outlook: Management believes current cash, cash equivalents, and marketable securities ($93.5 million) are sufficient to fund planned operations until the end of the second quarter of 2027.
- Financing: The company has an At-The-Market (ATM) offering program with approximately $113.8 million remaining available for future issuances. No shares were sold under this program in Q1 2026.
- Risks: The company faces significant risks common to clinical-stage biotechs, including the uncertainty of clinical trial results, regulatory approval timelines, and the need for additional capital. Failure to secure funding could force delays or curtailment of development programs.
Investor Verification Checklist
- Verify the sufficiency of the $93.5 million liquidity runway against the projected burn rate to reach the Q2 2027 milestone.
- Monitor the progress and data readouts of the Phase 2 pivotal portion of the PYNNACLE clinical trial for rezatapopt.
- Confirm the timeline and regulatory feedback for the planned Q1 2027 NDA submission.
- Assess the impact of the cessation of New Jersey tax credit sales on future cash flow and tax provisions.
- Review the status of the ATM program and potential dilution if additional equity financing is required before Q2 2027.